This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”
For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. BRC) told The Cannigma this week.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. cannabis researchers. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis.
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.
In recent months, the DEA has issued a select number of licenses to several groups in the US to allow for the cultivation of Cannabis for scientific research purposes. BRC works with research groups studying Cannabis and Cannabis flower to understand the plant in a scientific and federally regulated environment.
The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. organization to help advance scientific research into the potential medical benefits of cannabinoids.
Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.
Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.
We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.
Drug Enforcement Agency (DEA) to the Alcohol and Tobacco Tax and Trade Bureau (TTB), the Bureau of Alcohol Tobacco Firearms and Explosives (ATF). The bill includes several provisions for additional research to investigate the impact of legalization on public health, driving safety, and similar areas. Research, Training and Prevention.
The laboratory researched the fine print of every state’s rules for hemp sampling, THC potency, cannabinoid content, residual solvents, pesticides, mycotoxins, heavy metals, and microbiology. With that research, they created elaborate matrices to compare each mandate. Source: [link].
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.
According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug developmentresearch, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.
The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.
1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country. hemp industry in the U.S.,
.” 1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country.
. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.
By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). This report (abstract below) asks if Epidiolex is as efficient a drug as the manufacturer believes it to be.
Concrete extraction technicians, researchers, marijuana cultivators, marketers, marijuana processors, cannabis branding, and developers will all have a place in the industry. The more thorough your business plan is (ie, the more data you have) the easier it’ll be to fund your dispensary. Research Your Competitors.
The clues we have from existing literature indicate that while it’s probably safe, there’s insufficient clinical research to confirm or dispel it. Happily, the body of research into cannabis and psychedelics (including MDMA) is expanding fast, and it’s likely that better data on their interactions will become available in the near future.
We also speak with Mark Diener, Senior Product Manager of JULABO USA , which manufactures liquid temperature control instrumentation for the cannabis and hemp industries as well as for research, science, laboratories, pilot plants, and industrial processes. Press the Play button below to listen to the podcast. ? That’s gotten huge.
This is a well researched and detailed report and is, we suggest required reading. Research suggests that about one in five people will have an increase in paranoia as a result of the delta-9 THC after consuming cannabis. Every lab uses a different method so the data is not going to be consistent.”.
Although research is still underway, the effects of both short- and long-term exposure to pesticides by consuming (i.e., pursuant to Drug Enforcement Agency (DEA) or state-level programs). by eating or smoking cannabis) are unknown. Next Steps.
Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). if the plant is moved to Schedule III.
Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.
Today, every time I research these new cannabinoids, I inevitably see ones I have never heard of before. If someone wants to put a new substance (say, a newly discovered/developed cannabinoid) into a dietary supplement), it will be considered an NDI. People constantly ask me how X cannabinoid will be regulated.
DEA increases the cannabis research quota. Data indicates cannabis-containing vaping products losing market share to other cannabis products after recently reported health concerns. The DEA’sresearch quotas also include 384,460 grams of tetrahydrocannabinols, 40 grams of LSD, 50 grams of MDMA and 30 grams of psilocybin.
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. And time was an issue, since her research projects involved suicidal combat veterans with PTSD and stage 4 cancer patients who didn’t have long to live. Dr. Sue Sisley.
As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.
” These NACB national advertising standards clearly establish how important it is “that the Cannabis industry develop a robust set of business-approved guidelines to build trust amongst market participants and local state and national regulators. In early August , J.
There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. Which Cannabis Strains Are Highest in CBD, According to Lab Data? RELATED STORY. No wonder GW has been working behind the scenes to lobby for a de-facto monopoly on legal CBD.
Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Most reliable medical cannabis research filters into the U.S. Download : Cannabis Misinformation: What Does the DEA say about Marijuana?
As far as we know, Senate Majority Leader Mitch McConnell still isn’t willing to make even the slightest move toward legal weed; however, there have been some wicked, unforeseen developments. . Doctors say they look forward to seeing more research on the subject as more states allow marijuana in smokable form.
Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in.
FDA is actively developing regulations for CBD since hemp and its derivatives were federally legalized under the 2018 Farm Bill. Another current rider that prohibits the Justice Department from contravening an industrial hemp research program was proposed to be removed. Department of Agriculture. View the full article here.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content